MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehae101

Медицинская библиотека · European heart journal · 2024

Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry.

El-Chami Mikhael F, Garweg Christophe, Clementy Nicolas, Al-Samadi Faisal, Iacopino Saverio, Martinez-Sande Jose Luis, Roberts Paul R, Tondo Claudio, Johansen Jens Brock, Vinolas-Prat Xavier, Cha Yong-Mei, Grubman Eric, Bordachar Pierre, Stromberg Kurt, Fagan Dedra H, Piccini Jonathan P

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Prior reports have demonstrated a favourable safety and efficacy profile of the Micra leadless pacemaker over mid-term follow-up; however, long-term outcomes in real-world clinical practice remain unknown. Updated performance of the Micra VR leadless pacemaker through five years from the worldwide post-approval registry (PAR) was assessed.

METHODS

All Micra PAR patients undergoing implant attempts were included. Endpoints included system- or procedure-related major complications and system revision rate for any cause through 60 months post-implant. Rates were compared through 36 months post-implant to a reference dataset of 2667 transvenous pacemaker patients using Fine-Gray competing risk models.

RESULTS

1809 patients were enrolled between July 2015 and March 2018 and underwent implant attempts from 179 centres in 23 countries with a median follow-up period of 51.1 months (IQR: 21.6-64.2). The major complication rate at 60 months was 4.5% [95% confidence interval (CI): 3.6%-5.5%] and was 4.1% at 36 months, which was significantly lower than the 8.5% rate observed for transvenous systems (HR: .47, 95% CI: .36-.61; P < .001). The all-cause system revision rate at 60 months was 4.9% (95% CI: 3.9%-6.1%). System revisions among Micra patients were mostly for device upgrades (41.2%) or elevated thresholds (30.6%). There were no Micra removals due to infection noted over the duration of follow-up. At 36 months, the system revision rate was significantly lower with Micra vs. transvenous systems (3.2% vs. 6.6%, P < .001).

CONCLUSIONS

Long-term outcomes with the Micra leadless pacemaker continue to demonstrate low rates of major complications and system revisions and an extremely low incidence of infection.

Для цитирования: El-Chami Mikhael F, Garweg Christophe, Clementy Nicolas, Al-Samadi Faisal, Iacopino Saverio, Martinez-Sande Jose Luis, Roberts Paul R, Tondo Claudio, Johansen Jens Brock, Vinolas-Prat Xavier, Cha Yong-Mei, Grubman Eric, Bordachar Pierre, Stromberg Kurt, Fagan Dedra H, Piccini Jonathan P. Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry.. European heart journal. 2024. DOI: 10.1093/eurheartj/ehae101.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.